KITE-363

Phase 1Biologic

KITE-363 is one of 57 biologic programs targeting Relapsed and/or Refractory B-cell Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed And/or Refractory B-Cell LymphomaRecruiting

Chronic Inflammatory Demyelinating PolyneuropathyRecruiting

Autoimmune DiseaseEnrolling by invitation

Relapsed And/or Refractory B-Cell LymphomaPreclinical

Recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 1

Recruiting

Autoimmune DiseasePhase 1

Enrolling by invitation

Competition

Competitive Landscape

74 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Atgam

Novartis

Phase 2

2 2

Cytosar

Teva

Phase 2

1 3

Rayos

RRoxane Laboratories

Phase 2

2 4

Alkeran

AApotex Inc.

Phase 2

1 5

Vepesid

AAvyxa

Phase 2

1 6

Bicnu

MMelissa K Accordino

Phase 2

1 7

Cytoxan

BBaxter Healthcare Corporation

Phase 1

9 8

CAR-T Cell

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 2

3 9

Anti-CD19 CAR-T Cells

TThe Children's Hospital of Zhejiang University School of Medicine

Phase 2

2 10

CD19 CAR-T Cells

CChongqing Precision Biotech Co., Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

Chronic Inflammatory Demyelinating Polyneuropathy

NCT07304154

Q1 2030

PreclinicalRecruiting

Relapsed And/or Refractory B-Cell Lymphoma

NCT04989803

Clinical

Trials by Indication[1]

Long-term Follow-up1 trial

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Enrolling by invitation· Gilead logo

Gilead··NCT05041309·1,000 enrolled

Autoimmune Disease1 trial

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

Enrolling by invitation· Gilead logo

Gilead·Phase 1·NCT07038447·52 enrolled

Relapsed and/or Refractory B-cell Lymphoma1 trial

A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma

Recruiting· Gilead logo

Gilead·Preclinical·NCT04989803·247 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Relapsed/Refractory Autoimmune Neurologic Diseases

Recruiting· Gilead logo

Gilead·Phase 1·NCT07304154·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for KITE-363. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KITE-363 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KITE-363. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: Gilead

KITE-363

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q1 2030

Trials by Indication[1]

Long-term Follow-up1 trial

Autoimmune Disease1 trial

Relapsed and/or Refractory B-cell Lymphoma1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

References

Drug Info

Quick Facts

Related News